DTAN moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 15 of 16 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on DTAN as a result. In 25 of 31 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The 10-day moving average for DTAN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +2.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where DTAN advanced for three days, in 102 of 117 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 104 of 120 cases where DTAN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
The 10-day RSI Indicator for DTAN moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 20 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 27 of 30 cases where DTAN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for DTAN turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 20 similar instances when the indicator turned negative. In 16 of the 20 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DTAN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
DTAN broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
GSK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend. In 30 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on GSK as a result. In 50 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on November 04, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 29 of 46 cases over the following month. The odds of a continued upward trend are 63%.
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +0.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 197 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 145 of 258 cases where GSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 58 cases where GSK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.715) is normal, around the industry mean (-1.421). P/E Ratio (20.988) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.036) settles around the average of (0.038) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
GSK | ||
|---|---|---|
OUTLOOK RATING 1..100 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 36 | |
SMR RATING 1..100 | 34 | |
PRICE GROWTH RATING 1..100 | 47 | |
P/E GROWTH RATING 1..100 | 9 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| DTAN | GSK | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 80% | N/A |
| Stochastic ODDS (%) | 4 days ago 90% | 4 days ago 52% |
| Momentum ODDS (%) | 4 days ago 81% | 4 days ago 65% |
| MACD ODDS (%) | 4 days ago 80% | 4 days ago 63% |
| TrendWeek ODDS (%) | 4 days ago 87% | 4 days ago 64% |
| TrendMonth ODDS (%) | 4 days ago 82% | 4 days ago 58% |
| Advances ODDS (%) | 26 days ago 87% | 4 days ago 64% |
| Declines ODDS (%) | 29 days ago 69% | 6 days ago 55% |
| BollingerBands ODDS (%) | 4 days ago 73% | 4 days ago 47% |
| Aroon ODDS (%) | 4 days ago 87% | 4 days ago 56% |
A.I.dvisor tells us that DTAN and GSK have been poorly correlated (+13% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DTAN and GSK's prices will move in lockstep.
| Ticker / NAME | Correlation To DTAN | 1D Price Change % | ||
|---|---|---|---|---|
| DTAN | 100% | N/A | ||
| GSK - DTAN | 13% Poorly correlated | +0.51% | ||
| NICE - DTAN | 13% Poorly correlated | +2.04% | ||
| EL - DTAN | 13% Poorly correlated | +1.12% | ||
| SHEL - DTAN | 12% Poorly correlated | +1.33% | ||
| DAVA - DTAN | 10% Poorly correlated | -3.95% | ||
More | ||||
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.